ClinicalTrials.gg
CompletedNCT01523366Updated Aug 18, 2014Results posted

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

A Phase 4 interventional study of Ticagrelor and Clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-18.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Enrollment
48th of 78
53 · median 80
Started
2012
with 6 others
Phase 4
46 of 78
3 open now
Registered
9th of 78
by date
Lead sponsor
9 of 78
AstraZeneca

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 48th largest by enrollment, is one of 7 that started in 2012, is one of 46 in phase 4, and was the 9th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.

Read the detailed description

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease

03

Conditions studied

  • Stable Coronary Artery Disease

Keywords

  • Stable Coronary Artery Disease, CAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated before initiation of any study-related procedures
  • Male or female patients aged 18 years or older Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
  • Females must be post menopausal or surgically sterile Self-identified as Hispanic

Exclusion criteria

Exclusion Criteria:

  • Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
  • Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
  • Current smokers, including the use of tobacco containing products in the past 1 month of randomization
  • Patients requiring dialysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    Drug: Ticagrelor

  • Active comparator
    Clopidogrel

    Drug: Clopidogrel

Interventions

  • Min - 90mg/Max - 180mg tablets (loading dose)

  • 75mg (once daily)/Max - 600mg tablets (loading dose)

06

What researchers measure

Primary outcomes

  1. Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose

    Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value

    Time frame: At 2 hours after the loading dose

Secondary outcomes

  1. Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose

    Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value

    Time frame: At 0.5 and 8 hours after the loading dose

  2. Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8

    The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value

    Time frame: At 2 hours and 8 hours on Day 7 after multiple doses, and at the end of dosing interval on Day 8

  3. Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses

    The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.

    Time frame: Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose

  4. AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses

    The SD is a statistic using the log-transformed data and is not the geometric SD.

    Time frame: Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose

07

Results

Posted Aug 5, 2014
Limitations and caveats
Total N for the secondary outcome analysis after multiple doses and for PK measures was not the same for 2 hours, 8 hours and end of dosing. Only the first time point total N can be reported via the form. Row titles indicate N's where they differ.

Participant flow

Patients recruited from 6 centers in the United States from April 2012 until May 2013.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTicagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence
Started2020
Completed1920
Not completed10
Withdrew: Withdrawal by subject10
Washout Period - 10-14 Days
Participant flow — Washout Period - 10-14 Days
MilestoneTicagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence
Started1920
Completed1920
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTicagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence
Started1920
Completed1820
Not completed10
Withdrew: Not completed at least 7 days treatment10

Outcome measures

PrimaryInhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose

Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value

Time frame:
At 2 hours after the loading dose
Reported as:
Least squares mean · PRU
Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
PRUTicagrelor ArmClopidogrel Arm
Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose34.2 (12.4 to 55.9)201.4 (178.7 to 224.1)
Statistical analysis
  • Ticagrelor Arm vs Clopidogrel Arm · Mixed Models Analysis · p = <.001 · Mean difference (final values): -167.2 · 95% CI -197.0 to -137.4Ticagrelor minus clopidogrel
SecondaryInhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose

Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value

Time frame:
At 0.5 and 8 hours after the loading dose
Reported as:
Least squares mean · PRU
Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose
PRUTicagrelor ArmClopidogrel Arm
0.5 hours134.6 (105.1 to 164.1)269.8 (238.7 to 300.8)
8 hours34.0 (9.2 to 58.8)202.8 (176.6 to 229.0)
Statistical analysis
  • Ticagrelor Arm vs Clopidogrel Arm · Mixed Models Analysis · p = <.001 · Mean difference (final values): -135.2 · 95% CI -172.3 to -98.0Ticagrelor minus Clopidogrel
  • Ticagrelor Arm vs Clopidogrel Arm · Mixed Models Analysis · p = <.001 · Mean difference (final values): -168.9 · 95% CI -204.0 to -133.7Ticagrelor minus Clopidogrel
SecondaryInhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8

The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value

Time frame:
At 2 hours and 8 hours on Day 7 after multiple doses, and at the end of dosing interval on Day 8
Reported as:
Least squares mean · PRU
Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
PRUTicagrelor ArmClopidogrel Arm
2 hours on day 728.5 (8.0 to 49.0)179.0 (157.7 to 200.3)
8 hours on Day 7 -ticagrelor N=36 clopidogrel N=3338.7 (17.2 to 60.3)178.9 (156.5 to 201.4)
End of Dosing Interval on Day 8 - N's per 8 hours51.5 (29.8 to 73.1)182.1 (159.5 to 204.7)
Statistical analysis
  • Ticagrelor Arm vs Clopidogrel Arm · Mixed Models Analysis · p = <.001 · Mean difference (final values): -150.5 · 95% CI -176.9 to -124.1Ticagrelor minus Clopidogrel
  • Ticagrelor Arm vs Clopidogrel Arm · Mixed Models Analysis · p = <.001 · Mean difference (final values): -140.2 · 95% CI -168.4 to -111.9Ticagrelor minus clopidogrel.
  • Ticagrelor Arm vs Clopidogrel Arm · Mixed Models Analysis · p = <.001 · Mean difference (final values): -130.6 · 95% CI -158.0 to -103.2Ticagrelor minus clopidogrel.
SecondaryTicagrelor Plasma Concentrations After the Loading and Maintenance Doses

The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.

Time frame:
Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose
Reported as:
Geometric mean · ng/mL
Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
ng/mLTicagrelor (Treatment Period 1)Ticagrelor (Treatment Period 2)
Baseline (0 hours - pre-dose)1.2 ± 7.51.1 ± 1.8
0,.5 hours after the loading dose206.7 ± 413.1118.6 ± 352.0
2 hours after the loading dose - Period 2 N=18665.4 ± 566.2758.5 ± 716.6
8 hours after the loading dose376.9 ± 378.8479.6 ± 210.7
0 hours after multiple doses248.8 ± 238.9220.1 ± 295.8
2 hours after multiple doses609.3 ± 271.3466.5 ± 534.5
8 hours after multiple doses340.4 ± 283.8305.2 ± 301.6
End of dosing interval on Day 8 - Period 1 N=17283.3 ± 438.1200.7 ± 268.4
SecondaryAR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses

The SD is a statistic using the log-transformed data and is not the geometric SD.

Time frame:
Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose
Reported as:
Geometric mean · ng/mL
AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
ng/mLTicagrelor (Treatment Period 1)Ticagrelor (Treatment Period 2)
Baseline (0 hours - pre-dose)1.1 ± 2.31.0 ± 0.0
0,.5 hours after the loading dose13.6 ± 66.39.3 ± 26.9
2 hours after the loading dose - Period 2 N=18153.2 ± 128.6170.8 ± 156.5
8 hours after the loading dose113.8 ± 54.697.7 ± 61.9
0 hours after multiple doses113.3 ± 102.162.7 ± 76.7
2 hours after multiple doses183.4 ± 120.897.4 ± 147.9
8 hours after multiple doses132.8 ± 61.983.5 ± 71.4
End of dosing interval on Day 8 - Period 1 N=17124.8 ± 56.657.7 ± 83.5

Adverse events

Collected over Adverse events were collected from the time of signature of the informed consent throughout the treatment period including the follow up visit (approximately 11 weeks for each participant).. Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor Arm—0/40 (0%)5/40 (12.5%)
Clopidogrel Arm—0/39 (0%)6/39 (15.4%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTicagrelor ArmClopidogrel Arm
HeadacheNervous system disorders1/402/39
FallInjury, poisoning and procedural complications0/402/39
DyspneaRespiratory, thoracic and mediastinal disorders2/400/39
Abdominal pain upperGastrointestinal disorders0/401/39
Rib fractureInjury, poisoning and procedural complications0/401/39
NasopharyngitisInfections and infestations0/401/39
DiarrheaGastrointestinal disorders1/400/39
Oropharyngeal discomfortRespiratory, thoracic and mediastinal disorders1/400/39
MalaiseGeneral disorders1/400/39
Heart rate irregularInvestigations1/400/39

Baseline characteristics

Randomized Analysis Set for demography (N=40) - included all patients who signed informed consent and were randomized into the study. Pharmacodynamic (PD) Analysis Set for outcomes (N=38) - included all patients for whom PD data was available with no major protocol deviations thought to significantly affect the PD of ticagrelor or clopidogrel

Age, Customized
Age, Customized(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
<18 years000
Between 18 and 65 years101222
>=65 years10818
Sex: Female, Male
Sex: Female, Male(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
Female6612
Male141428
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
White171835
Not Reported325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
Hispanic or Latino202040
Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
United States202040
Region of Enrollment
Region of Enrollment(Participants)Ticagrelor (Period 1) Then Clopidogrel (Period 2) SequenceClopidogrel (Period 1) Then Ticagrelor (Period 2) SequenceTotal
United States202040
08

Study locations

5 sites
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Hollywood, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Linden, New Jersey, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2012
First posted
Feb 1, 2012
Start
Apr 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Aug 5, 2014
Last update
Aug 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01523366
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Apr 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Aug 5, 2014
Last update
Aug 18, 2014

Study contacts

Glenn Carlson, MD
study director · AstraZeneca PharmaceuticalsRoom C3B-718PO Box 15437Wilmington, DE 19850-5437 USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion